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Dear Editor,
Chronic hepatitis C (CHC) significantly affects the prognosis
of liver disease [1] and health related quality of life (HRQOL)
in patients with β-thalassemia major [2, 3]. CHC cure is a
crucial event in the prognosis of the disease, since prevents
fibrosis progression, decreases the risk of hepatocellular car-
cinoma (HCC), and improves survival. Standard antiviral
therapy with Pegylated Interferon (PEG-IFN) and Ribavirin
(RBV) has long been the standard of care, despite its limited
efficacy and increased ribavirin induced hematological ad-
verse events in thalassemic patients [4]. Recently, several nov-
el highly effective direct antiviral agents (DAAs) have been
approved for HCV treatment, with impressive cure rates,
higher than 90%, after 8–12 weeks of therapy and mild ad-
verse events [5], but there are no published reports
documenting the efficacy, safety and impact on QOL of avail-
able interferon-free antiviral regimens in patients with β-
thalassemia major.
We describe four cases of young patients with β-
thalassemia major and advanced fibrosis treated with
DAAs for CHC (Table 1). HCV genotype was 1b in all
p a t i e n t s e x c e p t o n e , wh i c h h a d g en o t y p e 4 .
Cryoglobulins were positive in two patients (cryocrit 1.6
and 3.2%) with no organ involvement. All patients were
previously non-responders to PEG-IFN ± RBV treatment.
Iron chelation drugs included subcutaneous desferrioxamine
and/or oral deferasirox. Antiviral therapy with sofosbuvir
(SOF) and ledipasvir (LDV) was started for 12 weeks. All
patients achieved sustained virologic response (SVR).
Treatment was safe and well tolerated, kidney function
remained stable, and the only adverse events were mild asthe-
nia and headache. Iron chelation concomitant medications
remained unmodified during treatment, as well as the frequen-
cy of blood transfusions. Ferritin levels decreased during ther-
apy in three patients, but in two of them returned to baseline
levels at FU3. A reduction of liver stiffness, assessed by tran-
sient elastography, occurred from baseline to FU3 in all sub-
jects. All SF36 scales related to mental health and to physical
health significantly improved at FU6 compared to baseline
(Table 2).
The present case series suggests that 12-week-combination
therapy of SOF/LDV is effective and safe in transfusion-
dependentβ-thalassemia patients with advanced liver fibrosis.
Remarkably, no impact of SOF on kidney function was ob-
served as e-GFR values remained stable during therapy and
FU.
To our knowledge, no data exist on the interactions be-
tween DAAs and iron chelation drugs. We employed SOF
and LDV in these patients because this drug combination is
associated with limited interactions [6]. Remarkably, in none
of the cases, it was necessary to modify iron chelation therapy,
and no changes in transfusion requests occurred. Moreover,
serum ferritin values, an indirect marker of iron chelation ef-
ficacy, showed an improvement during antiviral therapy in all
patients but one who reported poor compliance to iron chela-
tion therapy during DAA treatment.
A marked improvement of liver stiffness, which correlates
with fibrosis stage assessed by liver biopsy [7], was observed
in all patients. This result may be partly due to a reduction and
control of liver inflammation [8]; however, an initial regres-
sion of liver fibrosis might also have occurred, which is an
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important outcome in thalassemic patients, given their rapid
fibrosis progression.
Both thalassemia major and CHC affect HRQOL [2, 3, 9],
but the contribution of CHC to the impaired HRQOL of
Table 1 Biochemical and virological characteristics of HCV patients with thalassemia major during the study period
Parameters Baseline (T0) Treatment
week 4 (TW4)
End of treatment (EOT) Follow-up
week 12 (FU3)
Patient 1
Female
42 years
Hemoglobin (12–15 g/dL) 10.4 12.6 12.7 12.8
Total bilirubin (0.3–1.2 mg/dL) 2.6 1.32 1.64 2
ALT (7–35 U/L) 97 21 17 10
e-GFR (mL/min/1.73m2) 107 107 107 107
Serum ferritine (15–150 ng/mL) 184 130 88 166
HCV-RNA (IU/mL) 211.100 Undetectable Undetectable Undetectable
Liver stiffness (KPa) 10.5 – – 7.1
Patient 2
Female
43 years
Hemoglobin (12–15 g/dL) 10.9 11.7 10.8 11
Total bilirubin (0.3–1.2 mg/dL) 1.5 1.2 1.6 1.67
ALT (7–35 U/L) 24 14 11 13
e-GFR (mL/min/1.73m2) 112 112 106 112
Serum ferritine (15–150 ng/mL) 834 556 626 380
HCV-RNA (IU/mL) 1.121.181 Undetectable Undetectable Undetectable
Liver stiffness (KPa) 10 – – 7.3
Patient 3
Male
37 years
Hemoglobin (12–15 g/dL) 9.7 9.9 9.4 9.6
Total bilirubin (0.3–1.2 mg/dL) 2.72 2.81 2.63 2.38
ALT (7–35 U/L) 62 26 24 13
e-GFR (mL/min/1.73m2) 145 128 138 138
Serum ferritine (15–150 ng/mL) 544 667 346 462
HCV-RNA (IU/mL) 473.982 Undetectable Undetectable Undetectable
Liver stiffness (KPa) 10.4 – – 8.1
Patient 4
Male
38 years
Hemoglobin (12–15 g/dL) 11.5 10.9 11.1 10.7
Total bilirubin (0.3–1.2 mg/dL) 2.03 1.11 1.31 1.41
ALT (7–35 U/L) 47 19 35 42
e-GFR (mL/min/1.73m2) 128 128 128 128
Serum ferritine (15–150 ng/mL) 420 684 621 650
HCV-RNA (IU/mL) 4.419.000 Undetectable Undetectable Undetectable
Liver stiffness (KPa) 10 – – 7
Table 2 Physical and mental health related quality of life (HRQOL) scores in SF-36 scales before and 24 weeks after antiviral treatment of HCV
patients with Thalassemia major
Patient
number
Time Physical
functioning
Role-physical Bodily
pain
General
health
Vitality Social
functioning
Role-emotional Mental
health
1 T0 75 75 64 30 60 50 66 56
FU6 85 100 100 25 85 87 100 68
2 T0 50 50 41 5 30 37 33 40
FU6 85 100 84 56 85 87 100 76
3 T0 90 100 84 10 50 75 100 52
FU6 95 100 100 37 85 100 100 76
4 T0 75 80 72 20 50 55 60 54
FU6 91 94 90 35 83 90 100 70
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thalassemic patients has never been assessed. In our case se-
ries, a striking improvement of physical and mental dimen-
sions of health, assessed by SF-36 questionnaire, occurred in
all patients after HCV cure. This finding suggests that HCV
infection plays a prominent, though probably underestimated,
role on the impairment of HRQOL of thalassemic patients,
and that antiviral treatment has the capacity to affect also this
important aspect of patient’s health.
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